The effect of acute and chronic administration of the CCK1 receptor antagonist Dexloxiglumide (CR2017) on 24-h pH metry, LES motor and symptoms' pattern, in patients with gastroesophageal reflux disease (GERD). A randomized, double-blind, placebo controlled study.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2012
At a glance
- Drugs Dexloxiglumide (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 28 Jul 2011 New trial record